Quality Comes First

Discover Our Group:

MENARINI.COM

COUNTRIES

ASSAY MENU

menu

The power of comprehensiveness

The comprehensive panel of AFIAS assays enables to adopt the right approach for patients risk stratification in different clinical conditions. 

Every year over 10 million continue to fall ill with TB and over 1.3 million die due to tuberculosis.

Receiving treatment to prevent the development of active TB disease is particularly crucial for specific groups at risk (i.e. People living with HIV or who are receiving immunosuppressive therapy).

Currently, there is no gold standard for TB diagnosis. Conventional tests like tuberculin skin test (TST) or Mycobacterium tuberculosis antigen-based skin test (TBST), require multiple visits and trained staff to perform intradermal injection.

Treating latent TB infection is 90% effective hence easy and accessible TB testing is fundamental to prevent the development of TB disease and reduce transmission.

Item name

Cat. No.

Sample type

Analysis

Time to result

Storage temp.

AFIAS IGRA-TB

56618

WB

Qualitative

15 min

2 - 30 °C

Dengue fever is the most prevalent mosquito-borne viral disease, typically mild but potentially severe and life-threatening. It affects almost 50 % of the world’s population and is endemic in more than 100 nations.

AFIAS offer specific tests for dengue serology (IgM, IgG) and rapid dengue antigen (NS1) detection to follow up the illnesses at all stages and prevent more severe second infection.

A positive result of NS1 Ag test within 7 days of symptom onset enables early dengue infection diagnosis without further confirmatory test required while simultaneous detection of IgG-IgM helps to distinguish between recent primary dengue virus infection, or secondary dengue infection (generally more severe).

 

Item name

Cat. No.

Sample type

Analysis

Time to result Storage temp.

AFIAS DENGUE IgG-IgM

58650

WB/S/P

Qualitative

12 min

3 - 30 °C

AFIAS DENGUE NS1Ag

58649

WB/S/P

Qualitative

12 min

3 - 30 °C

Antimicrobial resistance (AMR) is one of the most pressing threats to health of the 21st century.

Most patients, both in health-care facilities and in primary health-care settings, receive initial antibiotic treatment based on a clinical assessment, without the use of microbiological tests

Multidisciplinary AMS programs have the purpose to ensure ‘the right antibiotic for the right patient, at the right time, causing the least harm to the patient and future patients’.

The successful implementation of AMS rely on accessible and rapid diagnostic tests that provide prescribers with quality-assured information about viral/bacterial infection and antibiotics susceptibility.

AFIAS MxA/CRP helps identify patients who most likely have viral infection, allowing physicians to consider

reserving antibiotics in this patient population and proceed with a watchful, waiting strategy. 

Item name

Cat. No.

Sample type

Working range

Time to result

Storage temp.

AFIAS MxA/CRP

56825

WB

MxA: 10-300 ng/mL
CRP: 1-200 mg/L

12 min

2 - 30 °C

 

Sepsis and septic shock are major healthcare problems. 48.9 million incident cases of sepsis worldwide.

Community-acquired pneumonia (CAP) is a major cause of sepsis globally.

Early identification of individuals at high risk for poor outcomes enhances survival by allowing for timely escalation of care.

AFIAS assays enables clinicians to implement timely interventions for patients at risks, which includes screening high-risk acutely ill patients and following standard treatment procedures.

CRP

  • Serial CRP measurement could be used to predict postoperative septic complications.
  • Typical pneumonia is often associated with elevations in CRP.
  • The NICE guidelines recommend considering a point‑of‑care CRP test in patients with symptoms of LRTIs.

IL-6

  • IL-6 is a valuable biomarker for diagnosing sepsis in accordance with Sepsis-3 definition and for confirming sepsis, with relatively high specificity.
  • Serum IL-6 levels could discriminate sepsis and distinguish septic shock from sepsis (Song).
  • IL-6 is a commonly detected cytokine and one of the most induced immune markers during co-infection.

PCT

  • PCT can support and predict the unfavourable prognosis of sepsis based on SEPSIS‐3.
  • In LRTIs, PCT guide decisions about antibiotics. Associated with lower rates of antibiotic exposure, antibiotic-related adverse effects, and mortality.
  • PCT evaluation guide antimicrobial treatment duration in patients with sepsis.

 

Item name

Cat. No.

Sample type

Working range

Time

to result

Storage temp.

AFIAS CRP

51957

WB/S/P

0.5 - 200 mg/L

3 min

2 - 30 °C

AFIAS PCT

53708

WB/S/P

0.1 - 100 ng/mL

12 min

2 - 8 °C

AFIAS PCT Plus G

58055

WB/S/P

0.02 - 50 ng/mL

12 min

2 - 30 °C

AFIAS IL-6

52316

WB/S/P

2 - 2500 pg/mL

12 min

2 - 30 °C

 

Acute upper respiratory tract infections are generally mild however severe complications may develop (i.e pneumonia, respiratory failure and superimposed bacterial infection) making difficult to take informed decision on cohorting, hospital admission as well as on therapeutic approach.

Rapid diagnosis of acute respiratory infections is crucial to enable prompt implementation of

control measures to prevent nosocomial influenza outbreaks and to minimize unnecessary antibiotics use.

AFIAS assays can dramatically reduce time-to-diagnosis for most frequent upper respiratory tract

infections helping clinicians to provide patient tailored therapy in a clinically actionable timeframe.

Item name

Cat. No.

Sample

type

Analysis

Time

to result

Storage

temp.

AFIAS COVID-19 Ag

51972

WB/S/P

Qualitative

10 min

2 - 30 °C

AFIAS COVID-19 Ab

51679

nasopharyngeal swab

Qualitative

12 min

2 - 30 °C

AFIAS COVID-19/Flu Ag Combo

52317

nasopharyngeal swab

Qualitative

20 min

2 - 30 °C

AFIAS COVID-19 nAb

53710

WB/S/P

Qualitative

20 min

2 - 30 °C

AFIAS Flu A+ B

53719

nasopharyngeal swab from symptomatic patients

Qualitative

10 min

2 - 30°C

AFIAS RSV

57988

nasopharyngeal swab from symptomatic patients

Qualitative

10 min

2 - 30°C

AFIAS RSV/FLU/COVID

58106

nasopharyngeal swab

Qualitative

20 min

2 - 30 °C

Acute gastroenteritis is among the most common diseases affecting people of all ages.

Norovirus and Adenovirus are most common and major causes of severe gastroenteritis both in child and adult population while Rotavirus infection is the leading cause of severe diarrhoea in children worldwide.

Acute gastroenteritis complications like dehydration and electrolyte disturbance, acute kidney injury, sepsis, can prove fatal for paediatric and elderly patients as well as for immuno-compromised or patients with co-morbidities.

Accelerating the diagnostic process with rapid results compared to conventional testing is crucial to decrease unneeded downstream procedures and to limit the time spent in isolation for patients reducing associated cost burden.

AFIAS offers easy and accessible on-site screening assays to accelerate detection of most common GI infection and reduce downstream procedures and the number of send-out tests.

Item name

Cat. No.

Sample type

Analysis

Time

to result

Storage temp.

AFIAS NORO

54427

Feces

Qualitative

12 min

2 - 30 °C

AFIAS ROTA

54428

Feces

Qualitative

12 min

2 - 30 °C

AFIAS ROTA/Adeno

54429

Feces

Qualitative

12 min

2 - 30 °C

 

AFIAS comphensive offer to monitor GI tract disease:

  • AFIAS Calprotectine: discriminate IBD from IBS 
  • AFIAS H. pylori SA: non invasive and rapid  test for the initial diagnosis of H.pylori infections as well to assess the efficacy of eradication therapy
  • AFIAS  Fecal Occult Blood (iFOB) for colorectal neoplasia (coming soon)

Item name

Cat. No.

Sample type

Analysis

Time

to result

Storage temp.

AFIAS H. Pylori

59301

Feces

Qualitative

12 min

2 - 30 °C

Calprotectin

58108

Feces

10-1,000 mg/kg

10 min

2 - 30 °C

AFIAS  Fecal Occult Blood (iFOB)

Coming soon

 

Monoclonal Antibodies (mAbs) are key in treating autoimmune diseases and solid tumors.

Multiple pharmacokinetics variables changing during time can influence mAbs exposure and individual adsorption.

Therapeutic drug monitoring (TDM) is a valuable tool to:

  • optimize dosing
  • personalize mAbs therapy and patient care
  • recapture biologic therapy response
  • prevent loss of response
  • improve drug efficacy cost-effectively

Results in 10 minutes for drug levels

Item name

Cat. No.

Sample type

Working range

Time to result

Storage temp.

 Afias Infliximab

56630

WB/S/P

0.2 - 50 ug/mL

10 min

2 - 30 °C

AFIAS Adalimumab

56629

WB/S/P

0.2 - 50 μg/mL

10 min

2 - 30 °C

AFIAS Etanercept

57853

WB/S/P

0,20-10 μg/mL.

10 min

2 - 30 °C

AFIAS Golimumab

57192

WB/S/P

0.20 - 30 μg/mL

10 min

2 - 30 °C

AFIAS Vedolizumab

57184

WB/S/P

2 - 60 μg/mL.

10 min

2 - 30 °C

AFIAS Ustekinumab

57182

WB/S/P

0.5 - 20 μg/mL

10 min

2 - 30 °C

AFIAS Trastuzumab

59110

WB/S

3‐150 μg/mL.

10 min

2 - 30 °C

Results in 12 minutes for free anti-drug antibodies

Item name

Cat. No.

Sample type

Working range

Time

to result

Storage temp.

AFIAS Free Anti-Infliximab

56631

WB/S

4 - 250 AU/mL

12 min

2 - 30 °C

AFIAS Free Anti-Adalimumab

56632

WB/S

3 - 20 AU/mL

12 min

2 - 30 °C

AFIAS Free Anti-Etanercept

57854

WB/S

10–100 ng/mL.

10 min

2 - 30 °C

AFIAS Free Anti-Golimumab

57793

WB/S

2 - 40 ng/mL

10 min

2 - 30 °C

AFIAS Free Anti-Vedolizumab

57771

WB/S

10 - 250 ng/mL

10 min

2 - 30 °C

AFIAS Free Anti-Ustekinumab

57794

WB/S

2.5-100 ng/mL

12 min

2 - 30 °C

AFIAS FreeAnti Trastuzumab

59111

WB/S

range: 8 – 500 AU/mL.

10 min

2 - 30 °C

22 minutes for total anti-drug antibodies

Item name

Cat. No.

Sample type

Working range

Time

to result

Storage temp.

AFIAS Total Anti-Infliximab

56832

S/P

8 - 250 AU/mL

22 min

2 - 30 °C

Venous thromboembolic disease (VTE) and Acute coronary syndrome (ACS) are 2 major cause of chest pain.

To establish the diagnosis a multi-modality approach has been developed and involves both imaging modalities and serology.

AFIAS offers a wide range of cardiac markers for cardiovascular diseases risk assessment.

Item name

Cat. No.

Sample type

Working range

Time to result

Storage temp.

AFIAS Tn-I Plus

53231

WB/S/P

0.01 - 15.00 ng/mL

12 min

2 - 30 °C

AFIAS CK-MB

53688

WB/S/P

3 - 100 ng/mL

12 min

2 - 8 °C

AFIAS CK-MB Neo

57814

WB/S/P

3 - 100 ng/mL

12 min

2 - 30 °C

AFIAS D-Dimer

53234

WB/S/P

50 - 10000 ng/mL

12 min

2 - 8 °C

AFIAS D-Dimer Neo

57815

WB/S/P

50 - 10000 ng/mL

12 min

2 - 30 °C

AFIAS NT-proBNP

53232

WB/S/P

10 - 30000 pg/mL

12 min

2 - 30 °C

AFIAS Myoglobin

53700

WB/S/P

2 - 500 ng/mL

12 min

2 - 8 °C

AFIAS Myoglobin Neo

57813

WB/S/P

2 - 500 ng/mL

12 min

2 - 30 °C

AFIAS Cardiac Triple

56820

WB/S/P

per item

12 min

2 - 8 °C

AFIAS ST2

54449

WB/S/P

3.1 - 200 ng/mL

12 min

2 - 30 °C

AFIAS BNP

56818

WB/P

5 - 5,000 pg/mL

12 min

2 - 30 °C

AFIAS Troponin T

55619

WB/S/P

10 - 20000 pg/mL

12 min

2 - 30 °C

AFIAS hsCRP

58110

WB/S/P

0.1 - 10 mg/L

3 min

2 - 30 °C

 

Item name

Cat. No.

Sample type

Analysis

Time

to result

Storage temp.

AFIAS HbA1c Neo

57398

WB

4 - 15 %NGSP

10 min

2 - 30 °C

AFIAS Insulin

59101

WB/S/P

2 – 300 μIU/mL

12 min

2 - 30 °C

AFIAS Microalbumin

52935

Urin

2 - 300 mg/L

12 min

2 - 30 °C

Item name

Cat. No.

Sample type

Analysis

Time

to result

Storage temp.

AFIAS PSA

53239

WB/S/P

0.5 - 100 ng/mL

15 min

2 - 8 °C

AFIAS PSA NEO

59166

WB/S/P

0.1 – 100 ng/mL

15 min

2-30°C

AFIAS AFP

53697

WB/S/P

0.5 - 350 ng/mL

15 min

2 - 30 °C

AFIAS CEA

53695

WB/S/P

1 - 500 ng/mL

15 min

2 - 30 °C

Item name

Cat. No.

Sample type

Working range

Time to result

Storage temp.

AFIAS TSH

53228

WB/S/P

0.09 - 80 uIU/mL (S/P) / 0.4 - 80 uIU/mL (WB)

15 min

2 - 30 °C

AFIAS TSH Plus

53233

WB/S/P

0.08 - 50 uIU/mL

12 min

2 - 30 °C

AFIAS T3

53693

S/P

0.5-5.0 ng/mL

10 min

2 - 30 °C

AFIAS Free T4

53694

WB/S/P

1 - 100 pmol/L

12 min

2 - 30 °C

AFIAS T4

58054

S/P

10.23 - 300 nmol/L

10 min

2 - 30 °C

AFIAS FSH

53701

WB/S/P

1 - 100 mIU/mL

12 min

2 - 30 °C

AFIAS Total βHCG

53698

WB/S/P

5 - 50000 mIU/mL

15 min

2 - 30 °C

AFIAS β-HCG Plus

53237

WB/S/P

2 - 1500 mIU/mL

12 min

2 - 30 °C

AFIAS LH

53705

WB/S/P

1 - 100 mIU/mL

12 min

2 - 30 °C

AFIAS Progesterone

56826

S/P

4.45 - 127.2 nmol/L

15 min

2 - 30 °C

AFIAS PRL

53709

WB/S/P

1 - 100 ng/mL

10 min

2 - 30 °C

AFIAS Testosterone

53230

S/P

0.5 - 12 ng/mL

15 min

2 - 30 °C

AFIAS Cortisol

53696

WB/S/P

80 - 800 nmol/L

10 min

2 - 30 °C

AFIAS AMH

53706

S/P

0.02 - 15 ng/mL

12 min

2 - 30 °C

AFIAS PTH

58831

WB/S/P

30-3000 pg/mL

12 min

2 - 30 °C

Item name

Cat. No.

Sample type

Working range

Time

to result

Storage temp.

AFIAS Ferritin

53229

S/P

10 - 1000 ng/mL

10 min

2 - 30 °C

AFIAS Vitamin D Neo

56910

WB/S/P

5 - 100 ng/mL

12 min

2 - 30 °C

AFIAS Anti-CCP Plus

53707

WB/S/P

3.2 - 300 U/mL

12 min

2 - 8 °C

AFIAS IgE

56831

WB/S/P

1 - 1000 IU/mL

12 min

2 - 30 °C